stockrowDianthus Therapeutics, Inc.
DNTH Healthcare Biotechnology
Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024.
- Revenue
- +205.6%
- EPS
- +16.1%
- Free cash flow
- −65.9%
Quarter to September 2026, against a year earlier
Follow DNTH
Alert me
Dianthus Therapeutics, Inc. (DNTH) Return on equity
Dianthus Therapeutics, Inc.'s return on equity over the twelve months to 30 September 2026 was −22.6%, up 15.8 percentage points from fiscal 2025 (−38.4%). Over the past ten years it has ranged from −111.3% (fiscal 2018) to 139.3% (fiscal 2017); the current reading is higher than 70% of that period. That is above the Biotechnology industry median of −52.0% and above the Healthcare sector median of −26.0%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −38.4% | (5.78) |
| FY2024 | −32.6% | 37.37 |
| FY2023 | −70.0% | (25.58) |
| FY2022 | −44.4% | 0.55 |
| FY2021 | −44.9% | 7.63 |
| FY2020 | −52.6% | 0.96 |
| FY2019 | −53.5% | 57.75 |
| FY2018 | −111.3% | (250.54) |
| FY2017 | 139.3% | 101.08 |
| FY2016 | 38.2% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | 92.2% |
| MANE Veradermics Incorporated compare | 0.00% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −8.08% |
| DNTH Dianthus Therapeutics, Inc. | −22.6% |
| CRSP CRISPR Therapeutics AG compare | −25.6% |
| DFTX Definium Therapeutics, Inc. compare | −64.1% |
| ERAS Erasca, Inc. compare | −78.3% |
| COGT Cogent Biosciences, Inc. compare | −146.6% |
| TVTX Travere Therapeutics, Inc. compare | −252.8% |
| Biotechnology industry median | −52.0% |
| Healthcare sector median | −26.0% |
| Market median | 1.01% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on DNTH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement